Literature DB >> 26420045

Assessment of the psychometric properties of the Chinese Impact of Vision Impairment questionnaire in a population-based study: findings from the Singapore Chinese Eye Study.

Eva K Fenwick1, Peng Guan Ong2, Charumathi Sabanayagam2,3, Gwyn Rees1, Jing Xie1, Edith Holloway1, Ching-Yu Cheng2,4,3, Tien Y Wong2,4,3, Blanche Lim2, Pok Chien Tan2, Ecosse L Lamoureux5,6,7,8.   

Abstract

PURPOSE: We investigated whether the Chinese impact of vision impairment (IVI) questionnaire is valid to generate reliable person estimates in a population-based sample.
METHODS: VRQoL was measured using the 32-item Chinese version of the IVI questionnaire in the Singapore Chinese Eye Study (2009-2011), a population-based study of the prevalence and risk factors for VI and eye diseases in Chinese Singaporeans. Rasch analysis was used to assess the Chinese IVI's response category functioning, precision, unidimensionality, targeting and differential item functioning. The ability of the Chinese IVI to discriminate participants along the spectrum of VI demonstrated criterion validity.
RESULTS: Of the 3353 participants, 27.2 % (n = 912) had VI (presenting visual acuity <6/12, better eye). Response categories were collapsed from six to four to resolve disordered thresholds. The Chinese IVI initially demonstrated multidimensionality and was split into three scales: 'Reading and Accessing Information'; 'Mobility and Independence'; and 'Emotional Well-being'. All three scales were unidimensional and demonstrated excellent range-based precision (all reliability coefficients 0.97), following removal of three misfitting items. Mean person measures decreased with worsening VI (e.g. Reading: none (7.50 logits); mild (6.99 logits); moderate (6.44 logits); and severe (3.01 logits) VI; p < 0.001).
CONCLUSIONS: A three-dimensional 29-item Chinese IVI is a valid tool to assess the impact of VI on VRQoL in a large population-based sample, comprising over a quarter of participants with VI. The 28-item English IVI is also likely to be valid for use in population-based studies; however, this must be demonstrated empirically in future studies.

Entities:  

Keywords:  Chinese impact of vision impairment questionnaire; Population-based; Rasch analysis; Reliability; Vision impairment

Mesh:

Year:  2015        PMID: 26420045     DOI: 10.1007/s11136-015-1141-1

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  33 in total

1.  Depression and disability associated with impaired vision: the MoVies Project.

Authors:  B W Rovner; M Ganguli
Journal:  J Am Geriatr Soc       Date:  1998-05       Impact factor: 5.562

2.  Vision-specific quality-of-life research: a need to improve the quality.

Authors:  Ecosse Lamoureux; Konrad Pesudovs
Journal:  Am J Ophthalmol       Date:  2011-02       Impact factor: 5.258

3.  Psychometric properties of the Veterans Affairs Low-Vision Visual Functioning Questionnaire.

Authors:  Joan A Stelmack; Janet P Szlyk; Thomas R Stelmack; Paulette Demers-Turco; R Tracy Williams; D'Anna Moran; Robert W Massof
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-11       Impact factor: 4.799

4.  The impact of vision impairment questionnaire: an assessment of its domain structure using confirmatory factor analysis and rasch analysis.

Authors:  Ecosse L Lamoureux; Julie F Pallant; Konrad Pesudovs; Gwyn Rees; Jennifer B Hassell; Jill E Keeffe
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-03       Impact factor: 4.799

5.  Vision-specific distress and depressive symptoms in people with vision impairment.

Authors:  Gwyneth Rees; Hui Wen Tee; Manjula Marella; Eva Fenwick; Mohamed Dirani; Ecosse L Lamoureux
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-02-17       Impact factor: 4.799

6.  Vision impairment, ocular conditions, and vision-specific function: the Singapore Malay Eye Study.

Authors:  Ecosse L Lamoureux; Elaine W Chong; Julian Thumboo; Hwee Lin Wee; Jie Jin Wang; Seang-Mei Saw; Tin Aung; Tien Y Wong
Journal:  Ophthalmology       Date:  2008-06-26       Impact factor: 12.079

7.  Body mass index and retinopathy in Asian populations with diabetes mellitus.

Authors:  David Rooney; Weng Kit Lye; Gavin Tan; Ecosse L Lamoureux; Mohammad Kamran Ikram; Ching-Yu Cheng; Neelam Kumari; Ying Feng Zheng; Paul Mitchell; Jie Jin Wang; Tien Y Wong; Charumathi Sabanayagam
Journal:  Acta Diabetol       Date:  2014-06-01       Impact factor: 4.280

8.  The PedsQL as a patient-reported outcome in children and adolescents with Attention-Deficit/Hyperactivity Disorder: a population-based study.

Authors:  James W Varni; Tasha M Burwinkle
Journal:  Health Qual Life Outcomes       Date:  2006-04-21       Impact factor: 3.186

Review 9.  Patient-centred measurement in ophthalmology--a paradigm shift.

Authors:  Konrad Pesudovs
Journal:  BMC Ophthalmol       Date:  2006-06-15       Impact factor: 2.209

10.  Abbreviated World Health Organization Quality of Life questionnaire (WHOQOL-Bref) in north Indian patients with bronchial asthma: an evaluation using Rasch analysis.

Authors:  Ashutosh N Aggarwal; Ritesh Agarwal; Dheeraj Gupta
Journal:  NPJ Prim Care Respir Med       Date:  2014-06-12       Impact factor: 2.871

View more
  3 in total

1.  Reducing respondent burden: validation of the Brief Impact of Vision Impairment questionnaire.

Authors:  Eva K Fenwick; Ryan E K Man; Gwyn Rees; Jill Keeffe; Tien Y Wong; Ecosse L Lamoureux
Journal:  Qual Life Res       Date:  2016-08-24       Impact factor: 4.147

2.  Different impact of early and late stages irreversible eye diseases on vision-specific quality of life domains.

Authors:  Preeti Gupta; Eva K Fenwick; Ryan E K Man; Alfred T L Gan; Charumathi Sabanayagam; Debra Quek; Chaoxu Qian; Chui Ming Gemmy Cheung; Ching-Yu Cheng; Ecosse L Lamoureux
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

3.  Five levels of performance and two subscales identified in the computer-vision symptom scale (CVSS17) by Rasch, factor, and discriminant analysis.

Authors:  Mariano González-Pérez; Rosario Susi; Ana Barrio; Beatriz Antona
Journal:  PLoS One       Date:  2018-08-28       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.